Astellas Pharma Inc: Hyperphosphatemia trials
The registry lists 10 Hyperphosphatemia studies with Astellas Pharma Inc as lead sponsor. 0 are open to participants now and 0 have results posted.
Phase 1 1Phase 2 2Phase 3 5No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With HyperphosphatemiaCompletedNCT02753894Phase 2
- Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in JapanCompletedNCT02510274Phase 1
- Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal DialysisCompletedNCT01903213
- Post-marketing Surveillance of Kiklin Capsules in Hemodialysis PatientsCompletedNCT01901107
- Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on DialysisCompletedNCT01742611Phase 3
- A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on DialysisCompletedNCT01742585Phase 3
- A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on HemodialysisCompletedNCT01057407Phase 3
- A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal DialysisCompletedNCT01017276Phase 3
- Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on HemodialysisCompletedNCT00892749Phase 3
- A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on HemodialysisCompletedNCT00505037Phase 2